Spago Nanomedical has recently presented promising data from the ongoing phase I/IIa study Tumorad-01, where the company's candidate shows clear tumour uptake and a continued good safety profile. The results are considered proof-of-concept and mark an important step forward in the development. CEO Mats Hansen and CDO Paul Hargreaves visited BioStock's studio to talk more about the significance of the latest results, what is next in the program - and how they see the company's commercial opportunities going forward.
See the interview with CEO Mats Hansen and CDO Paul Hargreaves, in English, below.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.